Cytomegalovirus infections in solid organ transplantation: a review
P Ramanan, RR Razonable - Infection & chemotherapy, 2013 - synapse.koreamed.org
Cytomegalovirus (CMV) continues to have a tremendous impact in solid organ
transplantation despite remarkable advances in its diagnosis, prevention and treatment. It …
transplantation despite remarkable advances in its diagnosis, prevention and treatment. It …
Congenital cytomegalovirus infection: new prospects for prevention and therapy
EC Swanson, MR Schleiss - Pediatric Clinics, 2013 - pediatric.theclinics.com
Cytomegalovirus (CMV) is a ubiquitous herpesvirus spread by close interpersonal contact
through saliva, blood, genital secretions, urine, or breast milk that infects up to 90% of the …
through saliva, blood, genital secretions, urine, or breast milk that infects up to 90% of the …
New developments in the management of cytomegalovirus infection after transplantation
A Meesing, RR Razonable - Drugs, 2018 - Springer
Cytomegalovirus (CMV) continues to be one of the most important pathogens that
universally affect solid organ and allogeneic hematopoietic stem cell transplant recipients …
universally affect solid organ and allogeneic hematopoietic stem cell transplant recipients …
Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients
Cytomegalovirus (CMV) infection and disease are major complications in the renal
transplant recipient. The occurrence of CMV is associated with acute rejection, allograft …
transplant recipient. The occurrence of CMV is associated with acute rejection, allograft …
Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations
J Torre-Cisneros, JM Aguado, JJ Caston… - Transplantation …, 2016 - Elsevier
Cytomegalovirus (CMV) infection remains a major complication of solid organ
transplantation. Because of management of CMV is variable among transplant centers, in …
transplantation. Because of management of CMV is variable among transplant centers, in …
Human cytomegalovirus
RL Hodinka - Manual of clinical microbiology, 2015 - Wiley Online Library
Cytomegalovirus (CMV) belongs to a large family of herpesviruses that commonly infect
humans of all ages. Although infections with this virus are normally asymptomatic in healthy …
humans of all ages. Although infections with this virus are normally asymptomatic in healthy …
Detection of cytomegalovirus in patients with inflammatory bowel disease: where to biopsy and how many biopsies?
JD McCurdy, FT Enders, A Jones… - Inflammatory bowel …, 2015 - academic.oup.com
Background The potential negative impact of cytomegalovirus (CMV) in ulcerative colitis
(UC) and Crohn's disease (CD) warrants efforts to improve the yield of diagnostic …
(UC) and Crohn's disease (CD) warrants efforts to improve the yield of diagnostic …
The human cytomegalovirus decathlon: Ten critical replication events provide opportunities for restriction
DL Turner, RA Mathias - Frontiers in Cell and Developmental Biology, 2022 - frontiersin.org
Human cytomegalovirus (HCMV) is a ubiquitous human pathogen that can cause severe
disease in immunocompromised individuals, transplant recipients, and to the developing …
disease in immunocompromised individuals, transplant recipients, and to the developing …
Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation
J Kobashigawa, H Ross, C Bara… - Transplant Infectious …, 2013 - Wiley Online Library
Background Cytomegalovirus (CMV) causes several complications following cardiac
transplantation including cardiac allograft vasculopathy. Previous studies suggested that …
transplantation including cardiac allograft vasculopathy. Previous studies suggested that …
Evaluation of low-versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients
S Gabardi, N Asipenko, J Fleming, K Lor… - …, 2015 - journals.lww.com
Background Despite proven efficacy of prolonged cytomegalovirus (CMV) prophylaxis using
valganciclovir 900 mg/day, some centers use 450 mg/day due to reported success and cost …
valganciclovir 900 mg/day, some centers use 450 mg/day due to reported success and cost …